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Abstract
Background: In 2010, a universal nomenclature for varicella-zoster virus (VZV) clades was established, which is very
useful in the monitoring of viral evolution, recombination, spread and genetic diversity. Currently, information about
VZV clades has been disclosed worldwide, however, there are limited data regarding the characterization of
circulating VZV clades in China, even where varicella remains widely epidemic.
Methods: From 2008 to 2012, clinical samples with varicella or zoster were collected in General Hospital in eight
provinces and analyzed by PCR, restriction endonuclease digestion and sequencing. The viral clades were
determined by analysis of five single nucleotide polymorphisms (SNPs) within the 447-bp fragment of open reading
frame (ORF) 22, and the restriction fragment length polymorphisms (RFLPs) of ORF 38 (PstI), ORF 54 (BglI) and ORF
62 (SmaI) were evaluated to understand genetic diversity of VZV and determinate varicella vaccine adverse event
(VVAE).
Results: Seventy-seven varicella and 11 zoster samples were identified as being positive for VZV. The five SNPs
profile showed that the majority of VZV strains belonged to clade 2, but clade 5 and clade 4 strains were also
found in Guangdong. The RFLPs analysis of the DNA fragments of ORF 38, 54 and 62 showed that 85 of these
samples were characterized as PstI + BglI + SamI-, and the remaining three VZV strains from varicella patients were
characterized as PstI-BglI + SamI+ which is the genetic profile of VVAEs.
Conclusions: The study suggested that the predominant clade 2 VZVs had been continually circulating since at
least the 1950s in China. Nearly all VZV strains except VVAEs possessed the genetic profile of PstI + BglI + Sam-.
However, the other clades were also found to be co-circulating with clade 2, especially in the border regions.
These results highlighted the need for the constant and broad use of virologic surveillance to provide an
important genetic baseline for varicella control and vaccination programs in China.
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Background
Varicella-zoster virus (VZV) is highly contagious and
causes two diseases. The primary infection results in
varicella (chickenpox), which usually occurs early in
life. Subsequently, the virus establishes a lifelong
latent infection in the sensory nerve ganglia, which
reactivates to cause zoster (shingles) under conditions
of declining immunity that are most commonly associ-
ated age [1].
Genotyping of VZV contributes to reveal viral di-
versity, recombination, evolution patterns and trans-
mission pathways. To achieve these goals, several
groups have published different schemes by using
molecular techniques such as the sequencing, restric-
tion fragment length polymorphisms (RFLPs) and
single nucleotide polymorphisms (SNPs) since the
1990s, however, the different nomenclature methods
will not facilitate interchange of information [2–7].
In 2010, Breuer et al. summarized the previous
nomenclature methods and proposed a novel nomen-
clature for VZV: clade 1–5 and two putative clades
(VI and VII). The new universal nomenclature will
be useful for the interchange and comparison of
genotyping data worldwide [6, 8, 9].
The universal childhood varicella vaccination pro-
gram was initiated in the United States (US) in 1995
[10, 11]. Currently, although varicella vaccines are
licensed and available throughout the world, the vari-
cella vaccination has been recommended as a universal
childhood immunization in only a small number of
countries including Canada, Germany, Australia, Korea
and Japan, where high coverage rates have been
attained, and vaccination has resulted in a significant
decline in varicella-related incidence, morbidity and
mortality [12, 13]. Due to the absence of varicella vac-
cination programs in most countries, varicella remains
a worldwide epidemic and was estimated that the global
varicella disease burden includes 4.2 million severe
cases and 4200 deaths annually [14]. In China, the
varicella vaccine is not included in the national
immunization program, which results in poor varicella
control and epidemic conditions, but it’s available for
purchase on private basis for vaccination of children.
However, application of the live-attenuated varicella
vaccine may cause varicella vaccine adverse events
(VVAE). Surveillance of the VVAE plays a key role in
evaluating side effects of the vaccine and helps physi-
cians in appropriate decision making.
This study describes the clade distribution and gen-
etic profile of circulating VZV strains throughout
China, and distinguishes vaccine strains from wild-type
strains. These data provide important genetic back-
ground that will facilitate efforts for controlling vari-
cella and zoster in China in the future.
Methods
Ethics statement
This study was approved by the Ethics Committee of
National Institute for Viral Disease Control and Preven-
tion, China Center for Disease Control and Prevention.
Individual written informed consent was obtained from
the parents or guardians of all participants.
Clinical samples
From 2008 to 2012, the suspected varicella or zoster
samples were collected from outpatients who were
clinically diagnosed with varicella or zoster in General
Hospitals. These patients stayed residentially in eight
provinces (Beijing, Jilin, Guangdong, Henan, Shaanxi,
Gansu, Sichuan, and Shandong) located in eastern,
southern, western, northern and central of mainland
China. These provinces cross subtropical (Guangdong)
and temperate climates (the other provinces) and
should be sufficiently representative (Fig. 1).
Viral DNA extraction and polymerase chain reaction (PCR)
Viral DNA was extracted from 200 μl vesicle fluid or
throat swab samples using the QIAamp DNA Mini Kit
(Qiagen, Valencia, CA). To characterize viral clades and
distinguish vaccine strains from wide-type strains, the
PCR amplification of ORF 22, 38, 54 and 62 were per-
formed in accordance with previously described proto-
cols [15–18]. One Chinese vaccine strain and one wide
type strain were used for the positive controls, the
DNase-free water was used for the negative control. The
447-bp region of ORF 22 (Strain Dumas, Genbank No.
X04370) encompassing five SNPs (37902, 38019, 38055,
38081, and 38177) was sufficient to characterize between
viral clades [2, 6]. However, discrimination between
clades 1 and 3 required the addition of a sixth SNP
(39394) to differentiate between the two clades. The
genetic markers of VZV that are most commonly con-
sidered in vaccine adverse events and epidemiological
studies include the RFLPs of ORFs 38 (PstI), 54 (BglI)
and 22 (SmaI) [16, 19]. The PCR assays were performed
using the PCR amplification kit (Takara, Dalian, China)
according to the manufacturer’s instruction. The tem-
plate amplifications were performed using a GeneAmp
9700 thermocycler (Applied Biosystems, Grand Island,
NY, USA). The PCR products were purified using a
QIAquick Gel Extraction Kit (Qiagen) and evaluated by
electrophoretic separation on 2 % agarose gels.
Sequencing and restriction enzyme reactions
The 447-bp region of ORF 22 were sequenced using an
ABI PRISM 3100 genetic analyzer (Applied Biosystems,
Hitachi, Japan) according to the manufacturer’s instruc-
tion, and the sequence data were assembled and edited
using Sequencher software version 4.0.5 (GeneCodes,
Xu et al. BMC Infectious Diseases  (2016) 16:542 Page 2 of 7
Ann Arbor, MI). The five SNPs were analyzed for VZV
clades identification using BioEdit version 7.0 (Tom
Hall, North Carolina State University, Raleigh, NC).
Restriction endonuclease digestion of the PCR prod-
ucts (ORF38, ORF54 and ORF62) was performed with
8 μl of the PCR products, 15 U endonuclease (PstI,
BglI and SmaI) (Takara, Dalian, China), and 2 μl of the
accompanying 10× endonuclease buffer. The final
reaction volume was adjusted to 20 μl with DNase-
and RNase-free water. The analysis of RFLPs was
performed according to the protocols previously
described in the literature [2, 16].
Results
Case confirmation
From 2008 to 2012, a total of 126 clinical samples were
collected in eight provinces, including 115 throat swabs
from 115 varicella patients and 11 vesicular fluids from
elven zoster patients. All patients were born and spent
their childhoods in China. No information was available
about the VZV exposure history including varicella
vaccination, except for five patients with mild varicella
within 3 weeks after varicella vaccination. The ages of
115 patients with varicella ranged between 3 and 25 years
(mean age 7.5 years); the ages of 11 patients with zoster
ranged between 40 and 68 years (mean age 50 years).
A total 88 of 126 samples were tested VZV positive
using the PCR screening of ORF 22 (447-bp), including
77 throat swabs from varicella patients and all 11 vesicu-
lar fluids from zoster patients. The throat swabs from
three of the five varicella patients with mild varicella
after varicella vaccination were also positive.
Viral clade determination
The 447-bp fragment (ORF 22) of 88 VZV samples was
successfully sequenced, the five SNPs profile (37902: G,
38019: G, 38055: C, 38081: C and 38177: A) disclosed
that most of endemic VZV strains were attributed to
Fig. 1 Distribution of VZV clades in China. 1. Numbers in parenthesis indicate the number of varicella and/or zoster strains; 2. The eight provinces
described in this study are labelled with an asterisk
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clade 2; however, one clade 5 (37902: A, 38019: G,
38055: T, 38081: C and 38177: G) strain from a 7-year-
old child and one clade 4 (37902: A, 38019: A, 38055: C,
38081: C and 38177: A) strain from a 64-year-old elder
with zoster were found in Guangdong in 2009. The
analysis of the sixth SNP (in the position 39394) was not
performed due to the lack of clade 1 or 3 strains
(Table 1).
Distinguishing vaccine strains from wild-type of VZV strains
For these positive VZV strains, three PCR amplifications
of ORF 38 (350-bp), 54 (222-bp) and 62 (268-bp) were
performed to distinguish vaccine strains from wild-type
strains. The three target bands were obtained for each of
the samples and digested with PstI, BglI and SmaI en-
zymes, respectively. The 350-bp amplification products
were cleaved to the 250 bp and 100 bp fragments by PstI
in most of the samples, except for three samples that
were collected from the Henan and Shaanxi provinces.
The 222-bp amplification products were cleaved to
137 bp and 85 bp by BglI in all of the samples. The two
genetic markers that were characterized in the most
VZV strains possessed the PstI + BglI+ pattern, with the
exception of 3 samples (PstI-BglI+). For the 268-bp frag-
ment, most VZV samples were cleaved to 153-bp, 79-bp,
and 36 bp (SmaI-) except the 3 strains that were cleaved
to 112-bp, 79-bp, 41-bp and 36 bp (SmaI+). The results
of the analysis of the three genetic makers indicated that
most of the VZVs belonged to wild-type strains, whereas
the three VZV strains from patients within 3 weeks after
varicella vaccination possessed the genetic profile (PstI-
BglI + SmaI+) of the Oka varicella vaccine (Table 1).
Discussion
Information about the molecular epidemiology of VZV
has been proven very useful for characterizing endemic
strains, tracing transmission pathways, and distinguishing
vaccine strains from wild-type strains. In 2010, Breuer
proposed a novel nomenclature for VZV: clade 1–5 and
two putative clades (VI and VII) that were identified by
Roman numerals until confirmed to be a clade. The new
universal nomenclature will be useful for the interchange
and comparison of genotyping data worldwide [6].
According to the universal nomenclature, the worldwide
distribution of VZV clades has been established. Clade 1
and clade 3 represent the dominate clades of the circulat-
ing VZV in Europe and the Americas, where the clade 4
and 5 strains are frequently identified due to the immigra-
tion of people with African origin. The clade VI strains
were also found in France (10 %) and Italy (11 %), and one
might speculate that clade VI strains are more common
than clade 3 strains in Southern Europe [20]. To date, only
one clade VII strain was exclusively isolated in the US in
2002 [21]; in Asia, VZV clade 2 has been the dominant
clade according to previous publications from Korea,
Japan, and China; however, clade 2 strains were not found
circulating in India, Nepal and Bangladesh, where clade 4
and 5 strains were dominant [2, 22–24].
Several previous publications (mostly in Chinese) have
disclosed information about the genotypes and genetic
profiles of VZV, but all of them focused on one province
or prefecture and were limited [2, 23, 25–32]. Overall, 420
VZV strains collected from 115 varicella patients and 305
zoster patients were characterized, which were detected
during the period from 2000 to 2015 in 13 provinces
(Table 2). In this study, 88 VZV strains collected from
Table 1 Genetic profile of eighty-eight VZV strains in eight provinces
Province Collection time No. of V or Z Clade Residue at ORF 22 position ORF38 (Pstl) ORF54 (Bgll) ORF62 (Small)
37902 38019 38055 38081 38177
Guangdong 2008–2010 V(21), Z(10) 2 G G C C A + + -
Guangdong 2009 V (1) 4 A A C C A + + -
Guangdong 2009 Z (1) 5 A G T C G + + -
Sichuan 2009 V (9) 2 G G C C A + + -
Beijing 2009 V (18) 2 G G C C A + + -
Henan 2010 V (1) 2 G G C C A + + -
Henan 2010 V (2a) 2 G G C C A - + +
Shaanxi 2012 V (1a) 2 G G C C A - + +
Shandong 2012 V(2) 2 G G C C A + + -
Gansu 2012 V (7) 2 G G C C A + + -
Jilin 2011–2012 V (15) 2 G G C C A + + -
1. V varicella; Z herpes zoster
2. All genome positions are based on the published sequence for the VZV reference strain: Dumas (Clade 1; Accession # XO4370)
3. Numbers in parenthesis indicate the number of varicella and/or zoster strains
4. ain right corner indicates the VVAEs
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eight provinces where no VZV investigation was reported
were characterized (Table 1). With the incorporation of
previously published data, this study contributes towards
the knowledge of the molecular epidemiology profile of
prevalent VZVs circulating in mainland China.
In northern China (Jilin, Liaoning, Beijing, Shanxi and
Inner Mongolian provinces), all clinical samples from
varicella patients since 2009 belonged to clade 2 [28, 31,
33]. However, three clade 1 or 3 VZV strains circulating
before 2000 were identified in Beijing by Loparev [2].
We speculate that the three clade 1 or 3 strains, which
were either imported or random cases, were not the
predominate clades in light of the current studies. In
western China, 120 VZV strains including four varicella
and 116 zoster samples were described in Xinjiang. The
results showed that four varicella strains belonged to
clade 2 and 116 zoster strains were distributed into 3
clades: 75 in clade 2, 40 in clade 5, and one in clade 1 or
3. Geography might cause multiple clade strains to co-
circulate because it borders Gansu province, where clade
2 strains predominate. Additionally, Southern Xinjiang
borders Pakistan and India, where clade 5 strains have
been circulating [34, 35]. Northern Xinjiang borders
Russia, where the clade 1 and 3 predominate [36]. The
genetic profiles of the RFLPs were characterized as 120
PstI+, 119 BgII+, one BgII- and 120 SmaI-, which indi-
cated that the genetic profile of most strains was PstI +
BgII+, except for one PstI + BgII- strain which is the gen-
etic profile of strains from Europe and North America
[30]. In Tibet, ten positive VZV strains were identified
and belonged to three clades, three in clade 2, three in
clade 1 or 3, and four in clade 5, which is probably due
to the special geographical location, as it borders
Pakistan, India and Nepal, where clades 1 or 3 and clade
5 predominate [2]. However, information about VZV
clades is currently unavailable for Yunan which is also a
very special location because it borders Myanmar,
Vietnam and Laos where the characterization of the
VZV clade has never been reported. The strengthening
of the virologic surveillance is critical in Yunan in the
near future. In southern China (Guangdong, Hunan and
Hubei provinces), a total of 206 positive VZV strains,
those isolated from 141 varicella and 65 zoster cases,
were identified. All of them belonged to clade 2, except
for one, which belonged to clade 5, and one that
belonged to clade 4 and was found in Guangdong. The
clade 5 strain was isolated from a 7-year-old varicella
patient. The clade 4 strain was isolated from a 63-year-
old zoster patient. Loparev et al. also published that
three clade 4 strains circulating before the year 2000
were found in Guangdong [2]. These results suggest that
the minority clade 4 and 5 strains might have been
circulating in Guangdong for a long time. This situation
might result from frequent international communication,
especially among the hundreds of thousands of Africans
residing in Guangdong. However, this should be further
validated by studies with large sample numbers in the
future. In eastern China (Shandong, Anhui, Shanghai,
Zhejiang, and Fujian provinces), the clade characterization
had been already highlighted, and all VZV strains from
varicella or zoster patients belonged to clade 2 except two
imported clade 5 strains based on the epidemiological
survey in Zhejiang (Tables 1 and 2) (Fig. 1) [37, 38].
Primary infection with VZV usually occurs during
childhood, at approximately 10 years of age [39]. Previ-
ously published data have shown that the strains of virus
causing zoster in a patient are identical to the primary
varicella strain that infected that patient [5]. The current
study shows that although other clades of VZV strains
were found to co-circulate in the border regions such as
Xinjiang, Tibet and Guangdong, the majority of VZV
strains from zoster patients belonged to clade 2. The
oldest patient was 68 years old, which indicated that the
clade 2 VZV strains had been continually circulating in
China since at least the 1950s.
Since the varicella vaccine is a live attenuated vaccine,
varicella-like rash after vaccination is rare but can occur
and is defined as a varicella vaccine adverse event
(VVAE), an increasingly common side effect of varicella
vaccination. The data of the Vaccine Adverse Event
Reporting System of the U.S. showed the mild varicella-
like rash would occur in 3 to 5 % of varicella vaccine
recipients [5]. The RFLP of a variable region is a useful
Table 2 Clade summary of the VZV strains isolated in mainland
China according to previous publications
Province Collection
time
No. of V or Z Clade References
Guangdong before 2000 V (3) 4 [2]
Beijing before 2000 V (3) 1 or 3 [2]
Shanghai 2007 V (8) 2 [25, 26]
Hubei 2008 V (16), Z (80) 2 [32]
Anhui 2007–2008 V (2), Z (17) 2 [23]
Liaoning 2009 V (3) 2 [33]
Inner Mongolia 2010 V (3) 2 [28]
Zhejiang 2009–2011 V (25) 2 (23), 5
(2)
[37]
Fujian 2010–2011 V (10), Z (34) 2 [41]
Tibet 2011 V (6), Z (4) 5 (3), 4 (4),
2 (3)
[27]
Xinjiang 2012–2013 V (4), Z (116) 2 (79), 5
(40), 1 or 3
(1)
[30]
Shanxi 2013 V (12) 2 [31]
Hunan 2013–2015 V (20), Z (54) 2 [29]
1. V varicella; Z herpes zoster
2. Numbers in parenthesis indicate the number of varicella and/or
zoster strains
Xu et al. BMC Infectious Diseases  (2016) 16:542 Page 5 of 7
tool to better understand VZV genetic characterization
and determination of varicella or zoster vaccine adverse
event. Previously RFLPs analysis showed that the major-
ity of wild-type strains from Europe and North America
(temperate climate) were PstI + BglI-. Wild-type strains
in Africa, Asia or the Caribbean (tropical and subtropical
climates) were PstI + BglI+, whereas the Oka vaccine
strain (vOka) was PstI-BglI+, and the Japanese Oka-like
wild-type strains were PstI-BglI+/PstI + BglI+, which in-
dicates that the RFLP analysis of the PstI and BglI failed
to distinguish wild-type strains from Oka vaccine strains
[8, 16, 18]. In 2000, RFLP analysis of the SmaI in ORF
62 was developed, which had been used to distinguish
vaccine strains from the wild-type strains. This marker
has been shown to be stable and can be confidently used
to identify vaccine strains [16]. However, with the identi-
fication of more unique SNPs within the vaccine virus, it
may be preferable to sequence the SNPs in order to
identify vaccine strains [9]. In this study, three VVAEs
from varicella patients in Shaanxi and Henan were iden-
tified according to the genetic profile of RFLPs: PstI-BgII
+ SmaI+ [16, 40], which is limited report about the
VVAEs in China until now. Although the varicella vac-
cine is not included in the national immunization pro-
gram in China, with the improvement of prevention
awareness of varicella, more children will be vaccinated,
which could result in more VVAEs. Therefore, it is very
important to enhance the ability to determine VVAEs
that will enable physicians to make informed decisions
and to relieve the burden of disease in patients.
Conclusions
In conclusion, this study confirms that VZV clade 2 repre-
sented the dominant clade nationwide and has been con-
tinually circulating in China since at least the 1950s.
There were other clade strains co-circulating with clade 2
in the border regions. The genetic profile of the 3 RFLPs
within ORF 38, 54 and 62 was usually PstI + BgII + SmaI-,
except for three VVAEs (PstI-BgII + SmaI+). This report
identified the clade distribution of the circulating VZV
strains throughout China and determined the VVAEs.
These results emphasize the identification of VVAEs and
the importance of a more systematic collection of VZV
strains, especially in the border regions, to propose more
effective control strategies and to establish an accurate
genetic baseline for VZVs in China in the near future.
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